Eisai will use the November Clinical Trials on Alzheimer’s Disease (CTAD) meeting to pair longer-term lecanemab trial follow-up with studies of how U.S. clinics use the drug.
For Clarity AD, Eisai plans to bring together follow-up from the study’s core phase and long-term extension, with initial findings spanning five years. The session is listed for 6-6:15 p.m. ET Nov. 16. CTAD runs Nov. 16-19 in Boston and online.
The program also includes LEADER, a multicenter retrospective study of lecanemab use for early Alzheimer’s disease at diverse U.S. treatment centers, three years after U.S. Food and Drug Administration (FDA) approval. Planned analyses will map treatment from its start into maintenance, examine outcomes by sex and assess at-home dosing by injection under the skin.
Separate research will assess real-world rates of amyloid-related imaging abnormalities, known as ARIA, and safety profiles in multiple countries. Another presentation will examine α-synuclein co-pathology in a Clarity AD cerebrospinal fluid substudy.
Lecanemab, marketed as Leqembi, is an antibody that targets aggregated soluble amyloid-beta protofibrils and insoluble amyloid-beta, according to Eisai. The company leads global development and regulatory submissions. Eisai and Biogen co-commercialize and co-promote the drug, with Eisai holding final decision-making authority.
Eisai’s release previewed the topics but did not provide detailed findings or participant counts for these presentations. CTAD says abstracts will be added to its app when the conference opens Nov. 16.
